

**Table S1. Studied biomarkers for the prediction of SAI, SAP or UTI.**

Marker	References	Outcome	Number of patients	Diagnostic criteria	Sample collection time (from stroke onset)	Direction	Clinical findings
<b>Albumin</b>	Dziedzic et al., 2006 [1]	SAP	705	Own criteria	First 36h	↓	Independent predictor of SAP
<b>Blood glucose</b>	Zonneveld et al., 2017 [2]	SAI, SAP and UTI	1676	CDC criteria [3]	At admission	↑	Independent predictor of SAI, SAP and UTI
<b>Copeptin</b>	Fluri et al., 2012 [4]	SAI, SAP and UTI	383	CDC criteria	First 72h	↑	Independent predictor of SAI, SAP and UTI
	Hotter et al., 2020 [5]	SAP	573	PISCES criteria [6]	First 40h	↑	Independent predictor of SAP
<b>CRP</b>	Fluri et al., 2012 [4]	SAI, SAP and UTI	383	CDC criteria	First 72h	↑	Independent predictor of SAI, SAP and UTI

	Bustamante et al., 2017b [7]	SAI	699 (systematic review)	Depending on the study	First 24h, 24-48h and 48-72h	↑	Independent predictor of SAI between 24 and 48h.
<b>FT3</b>	Suda et al., 2018b [8]	SAI	520	CDC criteria	At admission	↓	Independent predictor of SAI
<b>HDL</b>	Rodríguez-Sanz et al., 2013 [9]	SAI	1385	Own criteria	Morning following admission	↑	Independent predictor of lower risk of SAI
<b>Heart rate variability</b>	Günther et al., 2012 [10]	SAI	43	CDC criteria	First 48h and 4±1 days	NA	Independent predictor of SAI
<b>HLA-DR</b>	Zhang et al., 2009 [11]	SAI	53	Own criteria	1, 2, 4, 6 and 14 days after stroke	↓	Predictive value for SAI at days 1 and 2
	Hoffmann et al., 2017 [12]	SAP	479	CDC criteria		↓	

<b>IFN-γ</b>	Salat et al., 2013 [13]	SAI	92	CDC criteria	After administration of thrombolytic therapy	↓	Independent predictor of SAI
	Lin et al., 2016 [14]	SAI	54	ESPIAS clinical trial criteria [15]	First 24h	↓	Lower levels in patients with SAI
<b>IL1-ra</b>	Tanzi et al., 2011 [16]	SAI	112	Own criteria	1, 3, 7, 30 and 90 days	↑	Independent predictor of SAI at 72h
<b>IL-6</b>	Worthmann et al., 2015 [17]	SAI	56	Local clinical practice criteria	6h, 12h, 24h, 3 days and 7 days	↑	Higher levels in SAI patients at 12h, 24h, day 3 and day 7
	Kwan et al., 2013 [18]	SAI	82	Langhorne et al., 2000	First 72h	↑	Independent predictor of SAI
	Chamorro et al., 2006 [20]	SAI	110	ESPIAS clinical trial criteria	Admission, 1, 2, 3, 4 and 7 days	↑	Higher levels in patients with SAI at days 1, 2 and

							3
IL-10	Worthmann et al., 2015 [17]	SAI	56	Local clinical practice criteria	6h, 12h, 24h, 3 days and 7 days	↑	Independent predictor of SAI at 6h
	Chamorro et al., 2006 [20]	SAI	110	ESPIAS clinical trial criteria	Admission, 1, 2, 3, 4 and 7 days	↑	Independent predictor of SAI at admission
	Ashour et al., 2016 [21]	SAI	60	Engel et al., 2010; Stott et al., 2009	Admission, 4 and 7 days	↑	Independent predictor of SAI at admission
	Salat et al., 2013 [13]	SAI	92	CDC criteria	After the administration of thrombolytic therapy	↑	Independent predictor of SAI
IL-13	Salat et al., 2013 [13]	SAI	92	CDC criteria	After the administration of thrombolytic therapy	↑	Independent predictor of SAI

<b>LBP</b>	Worthmann et al., 2015 [17]	SAI	56	Local clinical practice criteria	6h, 12h, 24h, 3 days and 7 days	↑	Higher levels in SAI patients at 12h, 24h, day 3 and day 7
<b>MHR</b>	Sun et al., 2020 [24]	SAP	803	PISCES criteria	First 24h	↑	Independent predictor of SAP (highest quartile)
<b>miRNA-21</b>	Lin et al., 2016 [14]	SAI	54	ESPIAS clinical trial criteria	First 24h	↑	Higher levels in patients with SAI
<b>Monocyte count</b>	Sun et al., 2020 [24]	SAP	803	PISCES criteria	First 24h	↑	Independent predictor of SAP (highest quartile)
<b>MR-proADM</b>	Zapata-Arriaza et al., 2019 [25]	SAP	45	THRCT [26]	First 24h, 1 and 2 days	↑	Associated with SAP at 24h
	Bustamante et al., 2017a [27]	SAI	125	CDC criteria	Baseline (6h) and 24 hours (two different	↑	Independent predictor of SAI at baseline

					groups)		
<b>NK cells count</b>	De Raedt et al., 2015 [28]	SAI	59	CDC criteria	At admission, 1, 3, 5 and 7 days	↑	Higher levels in patients with SAI at admission
<b>NLR</b>	Nam et al., 2018 [29]	SAP	1317	PISCES criteria	First 24h	↑	Higher levels in patients with SAP
<b>PCT</b>	Fluri et al., 2012 [4]	SAI, SAP and UTI	383	CDC criteria	First 72h	↑	Independent predictor of SAI, SAP and UTI
	Hotter et al., 2020 [5]	SAP	573	PISCES criteria	First 40h	↑	Independent predictor of SAP
	Hug et al., 2011 [30]	SAP	50	Own criteria	Day 1 and 4	↑	No predictive value for SAP
<b>Prealbumin</b>	Ye et al., 2017 [31]	SAI	104	Own criteria	First day of admission	↓	Lower levels in patients with SAI

SAA	Azurmendi et al., 2017 [32]	SAI	40	CDC criteria	First 72h, 1, 3 and 5 days	↑	Associated with SAI at all time points
	Zapata-Arriaza et al., 2019 [25]	SAP	45	THRCT	First 24h, 1 and 2 days	↑	Associated with SAP in combination with suPAR at day 2
	Schweizer et al., 2020 [33]	SAI	283 (cohort A) and 367 (cohort B)	CDC criteria	First 72h (cohort A) and first 24h (cohort B)	↑	Independent predictor of SAI in both cohorts.
suPAR	Zapata-Arriaza et al., 2019 [25]	SAP	45	THRCT	First 24h, 1 and 2 days	↑	Associated with SAP in combination with SAA at day 2
	Bustamante et al., 2017a [27]	SAI	125	CDC criteria	Baseline (6h) and 24 hours (two different groups)	↑	Independent predictor of SAI at 24h

<b>Vitamin D</b>	Huang et al., 2019 [34]	SAP	863	CDC criteria	First day of admission	↓	Independent predictor of SAP
<b>WBC count</b>	Fluri et al., 2012 [4]	SAI, SAP and UTI	383	CDC criteria	First 72h	↑	Independent predictor of SAI, SAP and UTI

This table summarizes the biomarkers presented in section 4 alphabetically ordered. The table includes the reference of the publication in which each biomarker was studied, outcome of the biomarker, number of patients in the study, diagnostic criteria for infections, time of blood sample collection after stroke, direction of the expression alteration (upregulated ↑ or downregulated ↓) regarding the control group, and the clinical finding. The references can be found in the main text. Abbreviations: WBC: white blood cell, NLR: neutrophil-to-lymphocyte ratio, NK: natural killer, HDL: high density lipoprotein, NA: non-annotated, CRP: C-reactive protein, SAA: serum amyloid A, suPAR: soluble urokinase receptor, MR-proADM: mid-regional proadrenomedullin, PCR: procalcitonin, IL: interleukin, IFN- $\gamma$ : interferon- $\gamma$ , LBP: lipopolysaccharide binding protein, MHR: Monocyte to high-density lipoprotein cholesterol ratio, miRNA-21: microRNA-21, HLA-DR: Human Leukocyte Antigen – DR, FT3: free triiodothyronine, CDC: Centers for Disease Control and Prevention, THRCT: Thorax high-resolution computed tomography, SAI: Stroke-associated infection, SAP: Stroke-associated pneumonia, UTI: Urinary tract infection, PISCES: Pneumonia in stroke consensus.

## BIBLIOGRAPHY

1. Dziedzic T, Pera J, Klimkowicz A, Turaj W, Slowik A, Rog TM, et al. Serum albumin level and nosocomial pneumonia in stroke patients. *Eur J Neurol.* 2006;13:299–301.
2. Zonneveld TP, Nederkoorn PJ, Westendorp WF, Brouwer MC, Van De Beek Di, Kruijt ND. Hyperglycemia predicts poststroke infections in acute ischemic stroke. *Neurology.* 2017;88:1415–21.
3. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control.* 2008;36:309–32.
4. Fluri F, Morgenthaler NG, Mueller B, Christ-Crain M, Katan M. Copeptin, Procalcitonin and Routine Inflammatory Markers-Predictors of Infection after Stroke. *PLoS One.* 2012;7.
5. Hotter B, Hoffmann S, Ulm L, Montaner J, Bustamante A, Meisel C, et al. Inflammatory and stress markers predicting pneumonia, outcome, and etiology in patients with stroke: Biomarkers for predicting pneumonia, functional outcome, and death after stroke. *Neurol Neuroimmunol neuroinflammation.* 2020;7.
6. Smith CJ, Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, et al. Diagnosis of Stroke-Associated Pneumonia: Recommendations From the Pneumonia in Stroke Consensus Group. *Stroke.* 2015;46:2335–40.
7. Bustamante A, Vilar-Bergua A, Guettier S, Sánchez-Poblet J, García-Berrocoso T, Giralt D, et al. C-Reactive Protein in the Detection of Post-Stroke Infections: Systematic Review and Individual Participant Data Analysis. *J Neurochem.* 2017;141:305–14.
8. Suda S, Aoki J, Shimoyama T, Suzuki K, Sakamoto Y, Katano T, et al. Low Free Triiodothyronine at Admission Predicts Poststroke Infection. *J Stroke Cerebrovasc Dis [Internet]. Elsevier Inc.; 2018;27:397–403.* Available from: <https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.012>
9. Rodríguez-Sanz A, Fuentes B, Martínez-Sánchez P, Prefasi D, Martínez-Martínez M, Correas E, et al. High-density lipoprotein: A novel marker for risk of in-hospital infection in acute ischemic stroke patients? *Cerebrovasc Dis.* 2013;35:291–7.
10. Günther A, Salzmann I, Nowack S, Schwab M, Surber R, Hoyer H, et al. Heart rate variability - a potential early marker of sub-acute post-stroke infections. *Acta Neurol Scand.* 2012;126:189–96.
11. Zhang DP, Yan FL, Xu HQ, Zhu YX, Yin Y, Lu HQ. A decrease of human leucocyte antigen-DR expression on monocytes in peripheral blood predicts stroke-associated infection in critically-ill patients with acute stroke. *Eur J Neurol.* 2009;16:498–505.
12. Hoffmann S, Harms H, Ulm L, Nabavi DG, Mackert BM, Schmehl I, et al. Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia – The PREDICT study. *J Cereb Blood Flow Metab.* 2017;37:3671–82.
13. Salat D, Penalba A, García-Berrocoso T, Campos-Martorell M, Flores A, Pagola J, et al. Immunological biomarkers improve the accuracy of clinical risk models of infection

in the acute phase of ischemic stroke. *Cerebrovasc Dis.* 2013;35:220–7.

14. Lin SP, Ye S, Chen XH, Jiang HL, Mao HF, Chen MT, et al. Increased expression of microRNA-21 in peripheral blood mediates the down-regulation of IFN- $\gamma$  and increases the prevalence of stroke-associated infection. *J Neurol Sci* [Internet]. Elsevier B.V.; 2016;366:235–9. Available from: <http://dx.doi.org/10.1016/j.jns.2016.03.034>
15. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F, et al. The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial. *Stroke.* United States; 2005;36:1495–500.
16. Tanzi P, Cain K, Kalil A, Zierath D, Savos A, Gee JM, et al. Post-stroke infection: A role for IL-1ra? *Neurocrit Care.* 2011;14:244–52.
17. Worthmann H, Tryc AB, Dirks M, Schuppner R, Brand K, Klawonn F, et al. Lipopolysaccharide binding protein, interleukin-10, interleukin-6 and C-reactive protein blood levels in acute ischemic stroke patients with post-stroke infection. *J Neuroinflammation.* 2015;12:1–9.
18. Kwan J, Horsfield G, Bryant T, Gawne-Cain M, Durward G, Byrne CD, et al. IL-6 is a predictive biomarker for stroke associated infection and future mortality in the elderly after an ischemic stroke. *Exp Gerontol.* 2013;48:960–5.
19. Langhorne P, Stott D, Robertson L, MacDonald J, Jones L, McAlpine C, et al. Medical complications after stroke. *Stroke.* 2000;31:1223–9.
20. Chamorro Á, Amaro S, Vargas M, Obach V, Cervera Á, Torres F, et al. Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. *J Neurol Neurosurg Psychiatry.* 2006;77:1279–81.
21. Ashour W, Al-Anwar AD, Kamel AE, Aidaros MA. Predictors of early infection in cerebral ischemic stroke. *J Med Life.* 2016;9:163–9.
22. Engel O, Dirnagl U, Meisel A. Infection - An amendment to the stroke model guidelines. *J Exp Stroke Transl Med.* 2010;3:29–32.
23. Stott DJ, Falconer A, Miller H, Tilston JC, Langhorne P. Urinary tract infection after stroke. *QJM.* 2009;102:243–9.
24. Sun Y, Lu J, Zheng D, Qian J, Zhang H, Xing D, et al. Predictive value of monocyte to HDL cholesterol ratio for stroke-associated pneumonia in patients with acute ischemic stroke. *Acta Neurol Belg* [Internet]. Springer International Publishing; 2020; Available from: <https://doi.org/10.1007/s13760-020-01418-y>
25. Zapata-Arriaza E, Mancha F, Bustamante A, Moniche F, Pardo-Galiana B, Serrano-Gotarredona P, et al. Biomarkers predictive value for early diagnosis of Stroke-Associated Pneumonia. *Ann Clin Transl Neurol.* 2019;6:1882–7.
26. Zapata-Arriaza E, Serrano-Gotarredona P, Navarro-Herrero S, Moniche F, Pardo-Galiana B, Pallisa E, et al. Chest computed tomography findings and validation of clinical criteria of stroke associated pneumonia. *J Stroke.* 2019;21:217–9.
27. Bustamante A, García-Berrocoso T, Penalba A, Giralt D, Simats A, Muchada M, et al. Sepsis biomarkers reprofiling to predict stroke-associated infections. *J Neuroimmunol*

[Internet]. Elsevier B.V; 2017;312:19–23. Available from: <http://dx.doi.org/10.1016/j.jneuroim.2017.08.012>

28. De Raedt S, De Vos A, Van Binst AM, De Waele M, Coomans D, Buyl R, et al. High natural killer cell number might identify stroke patients at risk of developing infections. *Neurol Neuroimmunol NeuroInflammation*. 2015;2:e71.
29. Nam KW, Kim TJ, Lee JS, Kwon HM, Lee YS, Ko SB, et al. High neutrophil-to-lymphocyte ratio predicts stroke-associated pneumonia. *Stroke*. 2018;49:1886–92.
30. Hug A, Mürle B, Dalpke A, Zorn M, Liesz A, Veltkamp R. Usefulness of serum procalcitonin levels for the early diagnosis of stroke-associated respiratory tract infections. *Neurocrit Care*. 2011;14:416–22.
31. Ye S, Lin SP, Wu K, Fan Y, Xu M. Serum prealbumin is a predictive biomarker for stroke-associated infection after an ischemic stroke. *Int J Neurosci*. 2017;127:601–5.
32. Azurmendi L, Lapierre-Fetaud V, Schneider J, Montaner J, Katan M, Sanchez JC. Proteomic discovery and verification of serum amyloid A as a predictor marker of patients at risk of post-stroke infection: A pilot study. *Clin Proteomics*. 2017;14:27.
33. Schweizer J, Bustamante A, Lapierre-Fétaud V, Faura J, Scherrer N, Azurmendi Gil L, et al. SAA (Serum Amyloid A): A Novel Predictor of Stroke-Associated Infections. *Stroke*. 2020;51:3523–30.
34. Huang GQ, Cheng HR, Wu YM, Cheng QQ, Wang YM, Fu JL, et al. Reduced vitamin D levels are associated with stroke-associated pneumonia in patients with acute ischemic stroke. *Clin Interv Aging*. 2019;14:2305–14.